The goal of this project is to determine relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as pathology evolves from normal aging to very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNl will inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. ADNI2 continues the currently funded AD Neuroimaging Initiative (ADNI1), a public/private collaboration between academia and industry to study biomarkers of AD as well as a recently funded Grand Opportunities grant that supplements ADNl goals and activities (GO). New aspects of ADNl include enrolling subjects with early MCI (EMCI), F18 amyloid imaging, and obtaining all clinical/cognitive, lumbar puncture CSF and plasma biomarker, and MRI/PET data on all subjects. The goals of this ADNl renewal will be accomplished by: 1) continuing annual clinical/cognitive/MRI follow up of the 476 normal controls and late MCI (LMCI) subjects previously enrolled in ADNI1;2) following the 200 EMCI subjects enrolled in the GO ADNl grant;3) additional enrollment of new healthy controls (n=150), EMCI (n=100 which adds to the 200 subjects enrolled in GO), LMCI (n=150), and AD (n=150) subjects;4) performance of F18 amyloid PET (using F18 AV-45 from AVID, Inc.) on all new subjects enrolled in ADNI2, together with FDG PET, and to obtain a 2nd F18 amyloid PET on all remaining ADNI1, GO, and ADNI2 subjects 2 years after the baseline scan;5) continue to obtain annual clinical/cognitive/blood draw/lumbar puncture for CSF, and MRI on all subjects. All collected data will be processed and analyzed by ADNl investigators including the Biostatistical Core, and made available to all qualified scientists in the world who request a password, without embargo. Hypotheses developed from current ADNl data will be replicated and new hypotheses tested, especially concerning EMCI and F18 amyloid imaging. ADNl spawned large multisite projects in other countries. No other large multisite study in the world addresses these complex issues with the sample size and statistical power of this application.

Public Health Relevance

Alzheimer's disease (AD) causes cognitive impairment and dementia in millions of Americans and costs more than $100 billion/year in the USA. This ADNl project will provide new information which will greatly facilitate design of clinical treatment trials and will help develop new diagnostic techniques which identify AD at an early stage, ultimately leading to effective treatment and prevention of AD. REVIEW OF THE OVERALL PROGRAM

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AG024904-09S3
Application #
8899771
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Ryan, Laurie M
Project Start
2004-09-30
Project End
2015-07-31
Budget Start
2014-08-15
Budget End
2014-07-31
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Ueki, Masao; Tamiya, Gen; Alzheimer's Disease Neuroimaging Initiative (2016) Smooth-Threshold Multivariate Genetic Prediction with Unbiased Model Selection. Genet Epidemiol 40:233-43
Andrews, K Abigail; Frost, Chris; Modat, Marc et al. (2016) Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiol Aging 39:99-107
Franke, Barbara; Stein, Jason L; Ripke, Stephan et al. (2016) Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nat Neurosci 19:420-31
Cattell, Liam; Platsch, Günther; Pfeiffer, Richie et al. (2016) Classification of amyloid status using machine learning with histograms of oriented 3D gradients. Neuroimage Clin 12:990-1003
Loring, David W; Goldstein, Felicia C; Chen, Chuqing et al. (2016) False-Positive Error Rates for Reliable Digit Span and Auditory Verbal Learning Test Performance Validity Measures in Amnestic Mild Cognitive Impairment and Early Alzheimer Disease. Arch Clin Neuropsychol 31:313-31
Roussotte, Florence F; Narr, Katherine L; Small, Gary W et al. (2016) The C677T variant in MTHFR modulates associations between blood-based and cerebrospinal fluid biomarkers of neurodegeneration. Neuroreport 27:948-51
Coutu, Jean-Philippe; Goldblatt, Alison; Rosas, H Diana et al. (2016) White Matter Changes are Associated with Ventricular Expansion in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. J Alzheimers Dis 49:329-42
Hyun, Jung Won; Li, Yimei; Huang, Chao et al. (2016) STGP: Spatio-temporal Gaussian process models for longitudinal neuroimaging data. Neuroimage 134:550-62
Giraud, Rémi; Ta, Vinh-Thong; Papadakis, Nicolas et al. (2016) An Optimized PatchMatch for multi-scale and multi-feature label fusion. Neuroimage 124:770-82
Graff-Radford, Jonathan; Madhavan, Malini; Vemuri, Prashanthi et al. (2016) Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimers Dement 12:391-8

Showing the most recent 10 out of 1223 publications